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178Objective: Perioperative red blood cell transfusion is associated with increased morbidity and mortality after
coronary artery bypass grafting (CABG). Whether transfusion is a cause of these outcomes or serves as a surro-
gate for a high-risk patient population remains uncertain. This retrospective study tested the hypothesis that in-
creased preoperative risk profile of patients receiving transfusion would explain the relationship between red
blood cell transfusion and operative mortality in isolated CABG.
Methods: A total of 31,818 patients undergoing isolated CABG were entered into a statewide collaborative da-
tabase between January 2006 and June 2010. With the Society of Thoracic Surgeons risk calculator, patient co-
horts were stratified into 4 groups by predicted risk of mortality (PROM) of less than 2%, 2% to 5%, more than
5% to 10% and more than 10%. The association between blood transfusion and mortality was tested at each
stratum with a c2 test. A Breslow-Day test for homogeneity of odds ratios was used to test whether the 4
odds ratios of the strata were similar, and a Cochran-Mantel-Haenszel test was used to test the association be-
tween blood transfusion and mortality while controlling for predicted risk mortality strata.
Results: In all, 17,720 (55.7%) of all patients were transfused during the hospitalization. Incidence of transfu-
sion increased stepwise with risk level; 93.3% of patients with PROM greater than 10% received blood. Oper-
ative mortality was 2.1% overall, 0.6% among the 44.3% of patients who were not transfused, and 3.3% in the
transfused group (odds ratio, 6.19; P<.0001). The association between blood transfusion and mortality was sig-
nificant within each predicted risk stratum. Increased mortality associated with transfusion was statistically
equivalent across all predicted risk strata (P ¼ .1778). The association between blood transfusion and mortality
for all patients lessened somewhat when controlling for PROM (odds ratio, 2.99 vs 6.19), yet remained highly
significant (P<.0001).
Conclusions: The association between red blood cell transfusion and mortality after CABG is highly significant
and independent of increased preoperative risk status. The correlation persists after controlling for increased
PROM. (J Thorac Cardiovasc Surg 2012;143:178-85)Perioperative red blood cell transfusion is associated with
increasedmorbidity and both short- and long-termmortality
after coronary artery bypass grafting (CABG).1–5 The many
articles reporting these relationships have repeatedly
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The Journal of Thoracic and Cardiovascular Surgwho receive transfusion differs significantly from those
who do not. Consequently, whether transfusion is a cause
of these adverse outcomes or serves as a surrogate marker
for a patient population at higher risk remains uncertain.
This retrospective study tests the hypothesis that an
increased preoperative risk profile of patients receiving
transfusion would explain the relationship between red
blood cell transfusion and operative mortality in isolated
CABG.MATERIALS AND METHODS
Patient Population
The Michigan Society of Thoracic and Cardiovascular Surgeons Qual-
ity Collaborative is a multidisciplinary group consisting of all 33 hospitals
that perform adult cardiac surgery in the state of Michigan.6 All programs
use the Society of Thoracic Surgeons (STS) data collection form and sub-
mit data on a quarterly basis to both the STS database and the collaborative.
Data managers meet quarterly for ongoing education and training in data
abstraction and outcomes reporting. In addition, there are scheduled con-
ference calls and web-based seminars that focus specifically on issuesery c January 2012
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CABG ¼ coronary artery bypass grafting
PROM ¼ predicted risk of mortality
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Paone et al Perioperative Management
P
Mrelated to institutional quality initiatives or data definitions. Data audits are
conducted annually to ensure data integrity. Seventy-six data elements are
audited from a random sample of 20 cases at each center. These data ele-
ments include STSmorbidity andmortality risk model variables, intraoper-
ative data, and process and outcome measures. Data managers are
instructed to correct data abstraction errors and submit corrected data to
the STS during the next data harvest. For consistency, all audit visits are
conducted by the same 2 quality collaborative nurses. The last yearly audit,
completed in 2010, revealed 97% accuracy with 100% documentation of
30-day follow-up.
Between January 2006 and June 2010, a total of 31,818 patients under-
going isolated CABG were entered into the statewide collaborative data-
base and form the basis of this report. Patients undergoing both on-pump
and off-pump procedures were included. Through application of the STS
risk calculator,7 patient cohorts were stratified into 4 groups according to
predicted risk of mortality (PROM) of less than 2%, 2% to 5%, greater
than 5% to 10%, and greater than 10%. The STS risk model for CABG
predicts the risk of operativemortality andmorbidity on the basis of 30 pre-
operative patient demographic and clinical variables and can adjust for case
mix when comparing outcomes across institutions with different patient
populations.7
Statistical Analyses
The response rates for each of 23 preoperative patient characteristics
that were considered clinically relevant were summarized. The relation-
ships between these variables and both blood transfusion and mortality
were assessed in separate univariate analyses. Quantitative variables
were compared with 2-sided 2-sample t tests. Categoric variables were
compared between groups with c2 tests for association.
Because the distributions of PROM observed for both transfused and
nontransfused patients were severely skewed, a 2-sided Mann-Whitney-
Wilcoxon test was used to test whether there was a statistically significant
difference in the distribution of PROM between the 2 groups. A c2 test was
used to test whether there was an association between mortality and blood
transfusion. An odds ratio and a 95% confidence interval were computed to
estimate the strength of the association. The association between blood
transfusion and mortality was tested at each PROM stratum with a c2
test. A Breslow-Day test for homogeneity of odds ratios was used to test
whether the 4 odds ratios among the strata were similar, and a Cochran-
Mantel-Haenszel was used to test the association between blood transfu-
sion and mortality while controlling for PROM strata.
ACochran-Armitage trend test was used to test for a trend in transfusion
rate by increasing ordinal PROM strata. PROM was used as a predictor of
transfusion in a simple linear regression model. The effects of each risk
stratum in reference to the less than 2% PROM group were assessed
with the Wald c2 estimates.
A propensity score analysis was performed in a 2-step process to adjust
statistically for group differences in preoperative characteristics of pa-
tients who received transfusion versus patients who did not. In step 1,
the propensity score was obtained by calculating the predicted probabili-
ties in a multiple logistic regression on predicting transfusion. The model
included 17 preoperative variables that had significant relationships with
both transfusion and mortality according to univariate testing. Several
other variables were excluded because of limited responses. Patient re-
cords missing 1 or more responses for any of the 17 variables used inThe Journal of Thoracic and Cathe model were excluded, reducing the final sample size to 29,526. In
step 2, the strength of blood transfusion in predicting mortality was
then tested in another multiple logistic regression model after adjustment
for the propensity score.
Finally, as a sensitivity analysis, an additional multiple logistic regres-
sion model to test for a relationship between transfusion and mortality was
constructed. This model had as predictors, in addition to blood transfusion,
each of the 17 individual preoperative variables originally used to build the
propensity score.
Statistical analyses were performed with SAS statistical software (ver-
sion 9.2; SAS Institute, Inc, Cary, NC).RESULTS
Preoperative characteristics, including univariate com-
parisons for both transfusion status and mortality, are listed
in Table 1. The large majority of studied variables were sig-
nificantly related to both outcomes (P<.001). Preoperative
aspirin use within 5 days of surgery was the only variable
studied not significantly associated with either transfusion
status (P ¼ .690) or mortality (P ¼ .298). A total of
17,720 patients (55.7%) received red blood cell transfu-
sions during the index hospitalization. This transfusion
rate is comparable to the rate of 55.0% from the STS data-
base in a similar time frame.8
The incidence of transfusion increased stepwise with risk
level; 45% of patients at the lowest (<2% PROM) risk stra-
tum were transfused, and this rate increased to 93.3% for
patients with PROM greater than 10% (Table 2). Every
PROM stratum had a significantly higher transfusion rate
in reference to the lowest (<2% PROM) group, and this
trend was significant (P< .0001). PROM for the 44.3%
of patients not transfused was 1.3%, compared with 3.3%
for the transfused group (P<.0001).
Operative mortality was 2.1% for the entire group. There
was a significant association between blood transfusion and
mortality; 0.6% of those patients not receiving transfusion
died, compared with a mortality of 3.3% in the transfused
group (odds ratio, 6.19; P< .0001). The association be-
tween blood transfusion and mortality was also significant
within each PROM stratum (Table 3). Overall, there was
no significant difference between odds ratios when compar-
ing them across the PROM strata (P ¼ .1778). The associ-
ation between blood transfusion and mortality for all
patients decreased when controlling for the PROM (odds
ratio, 2.99 vs 6.19) yet remained highly significant
(P<.0001).
Sixteen of the 17 preoperative variables in a multiple lo-
gistic regression model were statistically significant predic-
tors of blood transfusion. Although left main coronary
disease was not significant, it was still considered in the pro-
pensity model because it had a significant association with
mortality (Table 4). After adjustment for group differences
built into the propensity score, blood transfusion remained
a highly significant predictor of mortality (odds ratio,
2.88; P<.001). Finally, a multiple logistic regression modelrdiovascular Surgery c Volume 143, Number 1 179
TABLE 1. Univariate analyses on blood transfusion and mortality by preoperative characteristics
Preoperative characteristic
No transfusion
(N ¼ 14,098)
Transfusion
(N ¼ 17,720) P value
Alive
(N ¼ 31,158)
Dead
(N ¼ 660) P value
Body surface area (m2, mean  SD) 2.1  0.2 2.0  0.3 <.001 2.1  0.3 2.0  0.3 <.001
Weight (kg, mean  SD) 94.8  19.4 84.6  19.5 <.001 89.2  20.0 83.5  22.3 <.001
Age (y, mean  SD) 62.2  10.2 67.4  10.6 <.001 65.0  10.7 70.7  10.8 <.001
Ethnicity (no.) <.001 <.001
Asian 75 (1%) 162 (1%) 231 (1%) 6 (1%)
Black 697 (5%) 1652 (10%) 2266 (8%)>T 83 (13%)
White 12,160 (91%) 14,404 (86%) 26,048 (88%) 516 (83%)
Hispanic 57 (0%) 85 (1%) 140 (0%) 2 (0%)
Native American 36 (0%) 33 (0%) 68 (0%) 1 (0%)
Other 324 (2%) 400 (2%) 710 (2%) 14 (2%)
Sex (no.) <.001 <.001
Female 1934 (14%) 6946 (39%) 8613 (28%) 267 (40%)
Male 12,163 (86%) 10,774 (61%) 22,544 (72%) 393 (60%)
Ejection fraction (%, mean  SD) 51.9%  11.4% 50.0%  13.1% <.001 51.0%  12.4% 45.4%  14.3% <.001
Last hematocrit (%, mean  SD) 40.9%  4.4% 36.5%  5.2% <.001 38.6%  5.3% 36.3%  5.4% <.001
Operative status (no.) <.001 <.001
Elective 5866 (42%) 5447 (31%) 11,179 (36%) 134 (21%)
Emergency 310 (2%) 963 (5%) 1180 (4%) 93 (15%)
Urgent 7918 (56%) 11,257 (64%) 18,766 (60%) 409 (64%)
Smoker, current or recent (no.) <.001 .028
No 9482 (70%) 12,853 (76%) 21,846 (73%) 489 (77%)
Yes 4066 (30%) 4117 (24%) 8037 (27%) 146 (23%)
Peripheral arterial disease (no.) <.001 <.001
No 12,382 (88%) 14,208 (80%) 26,138 (84%) 452 (68%)
Yes 1716 (12%) 3510 (20%) 5018 (16%) 208 (32%)
Cerebrovascular disease (no.) <.001 <.001
No 12,558 (89%) 14,311 (81%) 26,396 (85%) 473 (72%)
Yes 1539 (11%) 3407 (19%) 4759 (15%) 187 (28%)
Chronic lung disease (no.) <.001 <.001
No 11,618 (82%) 13,793 (78%) 24,977 (80%) 434 (66%)
Mild 1642 (12%) 2408 (14%) 3929 (13%) 121 (18%)
Moderate 523 (4%) 885 (5%) 1358 (4%) 50 (8%)
Severe 314 (2%) 633 (4%) 892 (3%) 55 (8%)
Diabetes (no.) <.001 .101
No 9026 (64%) 9989 (56%) 18,641 (60%) 374 (57%)
Yes 5072 (36%) 7731 (44%) 12,517 (40%) 286 (43%)
Hypertension (no.) <.001 .121
No 2351 (17%) 2220 (13%) 4490 (14%) 81 (12%)
Yes 11,747 (83%) 15,497 (87%) 26,665 (86%) 579 (88%)
Renal failure with dialysis (no.) <.001 <.001
No 13,449 (99%) 16,458 (97%) 29,319 (98%) 588 (91%)
Yes 106 (1%) 572 (3%) 623 (2%) 55 (9%)
Previous coronary artery bypass
grafting (no.)
<.001 <.001
No 13,728 (97%) 16,961 (96%) 30,085 (97%) 604 (92%)
Yes 370 (3%) 759 (4%) 1073 (3%) 56 (8%)
Heart failure (no.) <.001 <.001
No 13,085 (93%) 14,555 (82%) 27,216 (87%) 424 (64%)
Yes 1007 (7%) 3165 (18%) 3936 (13%) 236 (36%)
Myocardial infarction (no.) <.001 <.001
No 7548 (56%) 8128 (48%) 15,476 (52%) 200 (32%)
Yes 5999 (44%) 8843 (52%) 14,407 (48%) 435 (69%)
Myocardial infarction timing .018 .934
1–7 d 2441 (39%) 3783 (41%) 6043 (40%) 181 (40%)
(Continued)
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TABLE 1. Continued
Preoperative characteristic
No transfusion
(N ¼ 14,098)
Transfusion
(N ¼ 17,720) P value
Alive
(N ¼ 31,158)
Dead
(N ¼ 660) P value
Any other time 3788 (61%) 5424 (59%) 8942 (60%) 270 (60%)
Adenosine diphosphate receptor
inhibitors within 5 d (no.)
<.001 .006
No 6985 (92%) 7528 (84%) 14,240 (88%) 273 (83%)
Yes 634 (8%) 1367 (15%) 1945 (12%) 56 (17%)
Aspirin within 5 d (no.) .690 .298
No 2753 (20%) 3497 (20%) 6110 (20%) 140 (22%)
Yes 11,027 (80%) 13,849 (80%) 24,371 (80%) 505 (78%)
Left main disease 50% (no.) <.001 <.001
No 9671 (69%) 11,543 (65%) 20,821 (67%) 393 (60%)
Yes 4427 (31%) 6175 (35%) 10,335 (33%) 267 (40%)
Diseased vessels (no.) <.001 <.001
1 746 (5%) 503 (3%) 1232 (4%) 17 (3%)
2 3104 (22%) 3239 (18%) 6243 (20%) 100 (15%)
3 10,214 (73%) 13,947 (79%) 23,619 (76%) 542 (82%)
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Madding blood transfusion to those 17 preoperative variables
found to be significant predictors of transfusion and mortal-
ity, again demonstrated a significant relationship between
transfusion and mortality (odds ratio, 3.05; P < .001;
Table 5).
DISCUSSION
The association between blood transfusion and morbidity
and mortality in CABG is well established. In a series of
more than 8000 patients who underwent a variety of cardiac
surgical procedures, Murphy and colleagues2 reported that
red blood cell transfusion was strongly linked to increased
rates of stroke, myocardial infarction, renal impairment, in-
fections, prolonged stay, increased hospital costs, and early
and late mortality. Koch and associates3 reported compara-
ble relationships between transfusion and increased
morbidity and operative mortality and concluded, ‘‘Perio-
perative red cell transfusion is the single factor most reli-
ably associated with increased risk of postoperative
morbid events after isolated coronary artery bypass graft-
ing.’’ Other reports that have focused on specific outcomes,
including acute renal injury, pulmonary morbidity, and
heart failure, have shown similar results.9-13 Each of these
series exemplifies the available literature regarding
outcomes related to blood transfusion in cardiac surgery;
invariably, transfused patients have higher rates ofTABLE 2. Association between incidence of blood transfusions and predic
PROM Total (no.) Not transfused (no.) Transfuse
<2% 21,957 (69.0%) 12,074 (55.0%) 9883 (45
2%–5% 6722 (21.1%) 1656 (24.6%) 5066 (75
>5%–10% 2079 (6.5%) 297 (14.3%) 1782 (85
>10% 1060 (3.3%) 71 (6.7%) 989 (93
PROM, Society of Thoracic Surgeons predicted risk of mortality. *Probability based on a
trend test,<.0001.
The Journal of Thoracic and Camorbidity and mortality than those not transfused. Also
common to each of these reports, however, is the fact that
the demographic characteristics of the transfused group
significantly differ from those not receiving transfusion,
with transfused patients seeming to represent a cohort at
higher risk. Consequently, it remains uncertain whether
transfusion is the causal event leading to these worse
outcomes or rather is a marker for a sicker patient
population that is more likely to undergo transfusion for
many reasons.
We initiated this analysis with the hypothesis that a differ-
ence in the preoperative risk profile of patients receiving
transfusion would explain the increased risk associated
with transfusion. Demographic factors identified as signifi-
cant predictors of transfusion were essentially the same as
those that predicted mortality, lending support to our prem-
ise. The STS risk calculator7 for CABG was used to stratify
the study population into 4 cohorts specifically on the basis
of the preoperative PROM, and the PROM for the total
group of transfused patients in this study population was
indeed significantly greater than that for nontransfused
patients.
An additional finding of this study was the significant as-
sociation between PROM strata and the rate of transfusion.
As PROM increased, so too did the likelihood of transfu-
sion. Forty-five percent of patients in the lowest risk stratumted risk of mortality groups
d (no.) Odds ratio 95% Confidence interval P value*
.0%) Reference —
.4%) 3.74 3.51–3.98 <.0001
.7%) 7.33 6.46–8.31 <.0001
.3%) 17.01 13.35–21.68 <.0001
Wald c2 statistic for group effects. Overall probability based on a Cochran-Armitage
rdiovascular Surgery c Volume 143, Number 1 181
TABLE 3. Association between blood transfusions and mortality over predicted risk of mortality groups
Mortality
Transfused Odds ratio 95% Confidence interval P value*No. All Not transfused
All patients 31,818 660 (2.1%) 77 (0.6%) 583 (3.3%) 6.19 4.88–7.86 <.0001
PROM<2% 21,957 (69.0%) 160 (0.7%) 39 (0.3%) 121 (1.2%) 3.83 2.66–5.49 <.0001
PROM 2%–5% 6722 (21.1%) 198 (3.0%) 27 (1.6%) 171 (3.4%) 2.11 1.40–3.18 .0003
PROM>5%–10% 2079 (6.5%) 146 (7.0%) 8 (2.7%) 138 (7.7%) 3.03 1.47–6.25 .0016
PROM>10% 1060 (3.3%) 156 (14.7%) 3 (4.2%) 153 (15.5%) 4.15 1.29–13.35 .0098
PROM, Society of Thoracic Surgeons predicted risk of mortality. *Probability based on a c2 test for association.
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Mreceived blood; this increased sequentially to rates of
75.4% at a risk level of 2% to 5%, 85.7% at the greater
than 5% to 10% level, and 93.3% in the group with
a PROM of greater than 10%. This finding also supports
the idea that the relationship between transfusion and out-
comes is at least to some degree dependent on patient-
specific characteristics.
Consistent with other studies, patients receiving blood
transfusion had an operative mortality that was significantly
higher than that among those not transfused. This relation-
ship was significant for the study population as a whole andTABLE 4. Multivariable predictors of blood transfusion used in propensit
Variable Effect Adjusted od
Body surface area (m2) 0.119
Weight (kg) 1.009
Patient age (y) 1.039
Ethnicity
Asian vs white 1.53
Black vs white 1.78
Hispanic vs white 1.27
Native American vs white 0.79
Other vs white 1.11
Sex Female vs male 2.84
Ejection fraction (%) 0.991
Operative status
Emergency vs elective 3.65
Urgent vs elective 1.46
Smoker, current or recent Yes vs no 0.83
Peripheral artery disease Yes vs no 1.37
Cerebrovascular disease Yes vs no 1.35
Chronic lung disease
Mild vs no 1.10
Moderate vs no 1.19
Severe vs no 1.29
Renal failure with dialysis Yes vs no 3.78
Congestive heart failure Yes vs no 1.87
Myocardial infarction Yes vs no 1.11
Previous coronary artery
bypass grafting
Yes vs no 1.74
Left main disease Yes vs no 0.96
No. of diseased vessels
3 vs 1 2.24
2 vs 1 1.68
182 The Journal of Thoracic and Cardiovascular Surgwithin each of the 4 individual risk strata. Controlling for
PROM in the model diminished but did not fully explain
the strength of the relationship. The odds ratio was reduced,
but only from 6.19 to 2.99, and the association remained
highly significant. The association between transfusion
and mortality was additionally tested with the propensity
score analysis and a sensitivity analysis, with similar find-
ings for each model (odds ratios, 2.88 and 3.05, respec-
tively). These results strongly suggest an independent
effect of blood transfusion on outcome and therefore only
partially support our hypothesis.y score analysis (model size ¼ 29,526)
ds ratio Confidence interval Overall P value P value
0.073–0.193 — <.001
1.003–1.015 — .005
1.036–1.042 — <.001
<.001
1.13–2.06 .006
1.60–1.98 <.001
0.87–1.85 .225
0.47–1.34 .376
0.94–1.31 .220
2.63–3.07 — <.001
0.989–0.994 — <.001
<.001
3.11–4.27 <.001
1.38–1.55 <.001
0.78–0.89 — <.001
1.27–1.48 — <.001
1.25–1.46 — <.001
<.001
1.02–1.19 .020
1.05–1.36 .008
1.10–1.51 .002
2.98–4.79 — <.001
1.71–2.05 — <.001
1.05–1.18 — <.001
1.51–2.01 — <.001
0.91–1.02 — 0.172
<.001
1.95–2.58 <.001
1.45–1.95 <.001
ery c January 2012
TABLE 5. Predictability of blood transfusion on mortality with adjustment for preoperative associated variables (model size ¼ 29,526)
Variable Effect Adjusted odds ratio Confidence interval Overall P value P value
Blood transfusion Yes vs no 3.05 2.34–3.98 — <.001
Body surface area (m2) 0.243 0.085–0.693 — .008
Weight (kg) 1.016 1.003–1.030 — .014
Patient age (y) 1.042 1.032–1.052 — <.001
Ethnicity .033
Asian vs white 1.71 0.74–3.94 .210
Black vs white 1.54 1.19–1.99 .001
Hispanic vs white 0.77 0.19–3.18 .716
Native American vs white 0.80 0.11–6.01 .828
Other vs white 1.13 0.64–2.00 .671
Sex Female vs male 1.00 0.81–1.24 — .984
Ejection fraction (%) 0.988 0.982–0.995 — <.001
Operative status <.001
Emergency vs elective 3.84 2.81–5.26 <.001
Urgent vs elective 1.32 1.07–1.63 .011
Smoker, current or recent Yes vs no 0.92 0.74–1.15 — .470
Peripheral artery disease Yes vs no 1.49 1.23–1.80 — <.001
Cerebrovascular disease Yes vs no 1.36 1.12–1.66 — .002
Chronic lung disease <.001
Mild vs no 1.55 1.24–1.95 <.001
Moderate vs no 1.62 1.17–2.25 .004
Severe vs no 2.57 1.87–3.51 <.001
Renal failure with dialysis Yes vs no 2.43 1.72–3.51 — <.001
Congestive heart failure Yes vs no 1.74 1.42–2.12 — <.001
Myocardial infarction Yes vs no 1.36 1.12–1.65 — .002
Previous coronary artery
bypass grafting
Yes vs no 2.32 1.70–3.16 — <.001
Left main disease Yes vs no 1.04 0.87–1.24 — .644
No. of diseased vessels .378
3 vs 1 1.02 0.59–1.74 .954
2 vs 1 0.86 0.49–1.52 .599
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MThis investigation is subject to the limitations inherent in
any nonrandomized, retrospective, observational study de-
sign. The variability of transfusion rates as well as the indi-
cations for transfusion at both the institutional and
individual surgeon level were not evaluated. Potential dif-
ferences in outcome related to either the timing or volume
of transfusion were not analyzed. The database contains
no information regarding the storage duration of transfused
blood. Finally, because we used the STS risk algorithm to
stratify patients into defined risk groups, it is possible that
variables not included in that model could significantly af-
fect the relationships reported here.
Strengths of this study are the multicenter collaborative
source and the large data set used in the analysis. Although
all large multicenter databases suffer from concerns regard-
ing data completeness and accuracy, audits undertaken an-
nually give us confidence in the accuracy and integrity of
the data used to produce this report.14-16 The most recently
completed audit of the Michigan Society of Thoracic and
Cardiovascular Surgeons database revealed 97% overall
agreement and 100% confirmation of 30-day follow-up.The Journal of Thoracic and CaFurthermore, the comparable rates for transfusion and mor-
tality between these data and data from the STS database
tend to support the generalizability of these results.
Much has been written about the possible mechanisms by
which perioperative red blood cell transfusion may in fact
be harmful. Issues related to immunosuppressive and in-
flammatory effects and to poor oxygen delivery and red
blood cell deformity related to storage time and conditions
have been well summarized in a number of publications and
are beyond the scope of this discussion.2,17-21
Our results confirm a significant association between
blood transfusion and increased mortality after CABG
that is independent of preoperative risk status. Although
we cannot unequivocally attribute these differences to
transfusion alone, the results should provide further ratio-
nale for the aggressive implementation of blood conserva-
tion measures to limit the use of blood transfusion in
coronary surgery. Future investigations should evaluate po-
tential differences in outcome related to transfusion trig-
gers, intraoperative versus postoperative transfusion, and
the volume of blood transfused.rdiovascular Surgery c Volume 143, Number 1 183
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Dr Gus J. Vlahakes (Boston, Mass). First, I want to thank the
authors for providing the manuscript of the article and the presen-
tation well in advance of this meeting and also the Association for184 The Journal of Thoracic and Cardiovascular Surgthe privilege of discussing this. Second, I have no disclosures to re-
veal pertinent to this discussion.
Dr Paone, you and your coauthors have examined an important
subject of current interest that has been the subject of several stud-
ies in the last decade, the important ones being quoted in your
written article. With theMichigan Society of Thoracic and Cardio-
vascular Surgeons database, you have analyzed data from more
than 30,000 patients, and the power of this study rests in the large
number of patients derived from an audited, well-designed cardiac
surgical database. This foundation lends tremendous statistical
power and for all practical purposes eliminates the risk of type II
statistical errors.
The study confirms that after risk adjustment, red blood cell
transfusion remains a significant risk factor for complications
and mortality. The potential weakness of this study, however, as
you yourselves have pointed out, is the fact that the database
may not necessarily contain the data critical for analyzing transfu-
sion decisions, and in particular transfusion timing, relative to the
occurrence of complications, which themselves may mandate
transfusion.
As with previous studies on this subject, several important ques-
tions arise. Looking across the participating institutions, including
your own, do you have any preliminary analysis of transfusion trig-
gers for any institutions with fixed criteria such as hematocrit? If
so, were guidelines tailored to age, preoperative risk profile, or
other parameters? Importantly, can you determine from the data-
base or from participating institutions whether transfusions oc-
curred because of complications, as opposed to transfusion
before morbidity occurred? This question is based on your obser-
vation that the incidence of transfusion increased across the risk
strata that were studied. Previous studies have suggested that the
increment in risk produced by transfusion is proportional to the
number of units transfused. Are you able to confirm this from
your data?
Did you consider preoperative anemia as a factor leading to
transfusion, particularly in patients requiring more extensive pre-
operative evaluation and treatment? This question is suggested
by your observation that myocardial infarction within a week
of operation resulted in a higher incidence of transfusion, poten-
tially related to blood testing and care of the patient before
operation.
Previous studies have focused on 2 pathophysiologic mecha-
nisms to explain morbidity and mortality associated with transfu-
sions in the setting of cardiac surgery. One potential mechanism is
impaired oxygen transport with potential cardiac, neurologic, or
renal ischemia. The second purported mechanism is an increased
risk of infection, presumably as a result of immune response im-
pairment. Confirming that excess morbidity and mortality were
due to these mechanisms would further validate your findings.
Finally, some of these critical issues may be settled by the RE-
CESS trial currently in progress. This trial will test the hypothesis
that the risk of transfusion is related to the storage time of trans-
fused red blood cells.
Dr Paone. Thank you for your questions and your comments,
Dr Vlahakes. I will try to go through these one at a time.
With regard to your first point, we have asked a number of our
centers to provide the criteria that they use as transfusion triggers.
As you might expect, there is great variation in transfusionery c January 2012
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Mtriggers both during bypass and after the operation. We expected
to find that with a lower intraoperative transfusion trigger, at least
during bypass, those patients would be less likely to be transfused
in the operating room, and we did indeed find that. In addition, as
we looked at the incidence of transfusion postoperatively in these
patients, we expected that they would have a somewhat higher
rate, and they did. We also found that institutions that were
more likely to transfuse intraoperatively were also more likely
to transfuse postoperatively. So it is not all related to the trigger.
I think a lot of it has to do with your approach to blood transfu-
sion in general.
With regard to comparing transfusion rates and morbidities, we
did find—at least preliminarily, and we have not concluded the
analysis—that as you might also expect, as the risk level increases,
so does the risk of each of the major postoperative comorbidities.
Progressing from the less than 2% category to the 2% to 5% group
and so on, the rate of stroke increased, the rate of wound infection
increased, and so did rates of renal failure and the like. Again, we
are in the process of looking more closely at these data.
As we did mention in the article and at the end of our presenta-
tion here, we don’t have information yet on the volume of transfu-
sion. Again, it is a very large database, and so there are a lot of
things that we can and indeed plan to look at. A very preliminary
look at volumes of transfusion again confirms what you might ex-
pect from what we already know through the literature, which is
that as you increase the number of units of blood transfused to
each patient, their outcomes worsen. With respect to whether
this is related to the blood transfusion itself or is related to the co-
morbidities and the predicted risk, that analysis has not been fully
completed, and we will continue to look at this issue.
The role of anemia is questionable. Many articles that have
looked at these outcomes with regard to anemia or low hemato-
crits, particularly during bypass, have also shown relationships
with mortality and transfusion rate as well. One of the criticisms
of many of these studies looking at the role of hemodilutional ane-
mia in the operating room, particularly as it relates to the worsen-
ing outcomes, is that often the analyses do not include whether the
patients were transfused as well, and if so how much blood they
received. If you look at the demographic variables for patients
who get to lower levels of anemia, they tend to be the same exact
variables that predict transfusion. So it has been difficult at best to
try to discern whether it is actually the level of anemia that is caus-
ing the problem or the subsequent role of transfusion.
The mechanisms for how transfusion causes these outcomes, if
indeed it does, have been widely speculated on, including those
that you mentioned, immunosuppression, infection, and blood
storage time and duration. Again, those are issues that with the
size of the database we intend to try and look at to the best of
our ability in the future.
Dr Lokeswara Rao Sajja (Hyderabad, India). I congratulate
Dr Paone and colleagues on a nice presentation of a retrospective
analysis. There is enough evidence that the CABG performed with
off-pump technique has been associated with fewer homologous
blood transfusions. In this analysis, was the technique of off-
pump surgery applied in a comparable number of patients betweenThe Journal of Thoracic and Cathe 2 groups, those who received blood transfusion and those who
did not receive blood transfusion?
Dr Paone. These 31,818 patients were the total population of
patients undergoing CABG, including both on- and off-pump pro-
cedures. We did actually look briefly at the 2 groups. In the state of
Michigan, a little more than 9% of patients underwent off-pump
surgery. The transfusion rate in those cases was less than the trans-
fusion rate for the on-pump procedures, 41% versus about 57%. In-
terestingly, though, the mortality was about the same. The overall
mortalities were 2.2% in the off-pump cases and 2.1% in the on-
pump cases.
We then did the analysis that we showed for the entire group for
both groups separately. Although the strength of the relationship
was just slightly less for the off-pump cases, the relationship itself
held. When we adjusted for the predicted risk stratum, there was
still a significant relationship between transfusion itself—indepen-
dent of risk—and mortality in the off-pump cohort.
Dr Andrew C. Chang (Ann Arbor, Mich). Dr Paone, this study
and its analysis demonstrate the strength of a collaborative effort in
evaluating an important issue that crosses subspecialties in tho-
racic surgery. In the analysis, even though multivariate analysis
identified some important factors, has your group looked at the sig-
nificance of each of these factors with parsimonious model testing,
such as the Akaike information criterion, to determine the good-
ness of fit of the final model; that is, whether the use of transfusion
was as important as other comorbidities that are considered part of
the PROM score?
Dr Paone. We did not. We did the propensity score analysis,
and we subsequently did a standard multivariable analysis. Blood
transfusion again was an independent predictor, but that was the
extent of what we did.
Dr Michael Poullis (Liverpool, UK).We have repeated the ex-
act same study you have done in a single institution with 5500 pa-
tients and found exactly the same results as you have. The one
surprise finding, if you look at people who were discharged
home alive, their survival was not affected by blood transfusion,
which is a bit contrary to the literature. Have you looked at survival
and the effect of transfusion?
Dr Paone. Thank you for your question. No, we have not. We
have done some preliminary work that shows that at the lowest
risk level getting small amounts of transfusion does not seem to af-
fect survival. As I said, with the size of the database, we intend to
look at that a lot more deeply and to try and determine how we can
tease that out. This has been the question in this area for many
years. It has been clear that there is a relationship between mortal-
ity and transfusion. It has also been clear when you look at the data
that the patients who get transfusions tend to be sicker. And that is
what we have tried to sort out here. I think we have sorted it out
a bit, but clearly, more work needs to be done.
Dr Poullis. Yes, because I find it a little bit odd that the hazard
ratio of dying with transfusion is so high—you found 4, Murphy
found 6, we have 10 in Liverpool—and then as soon as you get dis-
charged home, it goes down to 1. It is probably the hosts more than
the blood. Of course, blood is bad, but I think it’s the hosts more
than the blood.rdiovascular Surgery c Volume 143, Number 1 185
